1. BellC, GrahamJ, EarnshawS, Oleen‑BurkeyM, Castelli‑HaleyJ, 
Johnson K. Cost‑effectiveness of four immunomodulatory 
therapies for relapsing‑remitting multiple sclerosis: A Markov 
model based on long‑term clinical data. J Manag Care Pharm 
2007;13:245‑61.
2. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, 
Baskerville J, et al. The natural history of multiple sclerosis: A 
geographically based study. I. Clinical course and disability. 
Brain 1989;112(Pt 1):133‑46.
3. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, 
Baskerville J, et al. The natural history of multiple sclerosis: 
A geographically based study 2. Predictive value of the early 
clinical course. Brain 1989;112(Pt 6):1419‑28.
4. Lublin FD, Reingold SC. Defining the clinical course of 
multiple sclerosis: Results of an international survey. National 
Multiple Sclerosis Society (USA) Advisory Committee on 
Clinical Trials of New Agents in Multiple Sclerosis. Neurology 
1996;46:907‑11.
5. Richards RG, Sampson FC, Beard SM, Tappenden P. Areview 
of the natural history and epidemiology of multiple sclerosis: 
Implications for resource allocation and health economic 
models. Health Technol Assess 2002;6:1‑73.
6. Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, 
Borm G; Functional Composite and Quality of Life in 
Avonex‑treated Relapsing Multiple Sclerosis Patients Study 
Group. Improvement of health‑related quality of life in relapsing 
remitting multiple sclerosis patients after 2 years of treatment 
with intramuscular interferon‑beta‑1a. J Neurol 2010;257:584‑9.
7. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, 
O’Connor P, et al. Randomized, comparative study of 
interferon beta‑1a treatment regimens in MS: The EVIDENCE 
trial. Neurology 2002;59:1496‑506.
8. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, 
Lisak RP, et al. Copolymer 1 reduces relapse rate and improves 
disability in relapsing‑remitting multiple sclerosis: Results of a phase III multicenter, double‑blind placebo‑controlled trial. 
The Copolymer 1 Multiple Sclerosis Study Group. Neurology 
1995;45:1268‑76.
9. Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, 
Forrestal F, Jongen P, et al. Long‑term subcutaneous interferon 
beta‑1a therapy in patients with relapsing‑remitting MS. 
Neurology 2006;67:944‑53.
10. Etemadifar M, Maghzi AH, Hoseinzadeh A. Comparing 
side effects of CinnoVex with Avonex in relapsing remitting 
multiple sclerosis patients. J Isfahan Med Sch 2009;27:93‑100.
11. Etemadifar M, Mazdeh M, Torabi HR, Ghaffarpour M, 
Azimian M, Salami S, et al. A report of multiple sclerosis 
patients treated by CinnoVex™ in Iran. Tehran Univ Med J 
2010;68:30‑6.
12. Nafissi S, Azimi A, Amini‑Harandi A, Salami S, 
Shahkarami MA, Heshmat R. Comparing efficacy and side 
effects of a weekly intramuscular biogeneric/biosimilar 
interferon beta‑1a with Avonex in relapsing remitting multiple 
sclerosis: A double blind randomized clinical trial. Clin Neurol 
Neurosurg 2012;114:986‑9.
13. Arababadi MK, Mosavi R, Khorramdelazad H, Yaghini N, 
Zarandi ER, Araste M, et al. Cytokine patterns after therapy 
with Avonex®, Rebif®, Betaferon® and CinnoVex™ in 
relapsing‑remitting multiple sclerosis in Iranian patients. 
Biomark Med 2010;4:755‑9.
14. Sharafaddinzadeh N, Majdinasab N, Ghiasian M, 
Moravej‑Aleali A. Efficacy of interferon β1a (Cinnovex) in 
relapsing‑remitting multiple sclerosis patients. Zahedan J Res 
Med Sci 2011;13:3‑6.
15. Hahl J, Hämäläinen H, Sintonen H, Simell T, Arinen S, 
Simell O. Health‑related quality of life in type 1 diabetes 
without or with symptoms of long‑term complications. Qual 
Life Res 2002;11:427‑36.
16. Ardito SQ, Bestetti RB, Cardinalli‑Neto A, Otaviano AP, 
NogueiraPR. Chronic renal impairment in patients with Chagas 
cardiomyopathy with chronic systolic heart failure: Prevalence 
and prognostic significance. Int J Cardiol 2011;152:133‑4.
17. Joshi VD, Mooppil N, Lim JF. Validation of the kidney 
disease quality of life‑short form: A cross‑sectional study of a 
dialysis‑targeted health measure in Singapore. BMC Nephrol 
2010;11:36.
18. Ghaem H, Borhani Haghighi A, Jafari P, Nikseresht AR. 
Validity and reliability of the Persian version of the 
multiple sclerosis quality of life questionnaire. Neurol India 
2007;55:369‑75.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: 
An expanded disability status scale (EDSS). Neurology 
1983;33:1444‑52.
20. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. 
Ahealth‑related quality of life measure for multiple sclerosis. 
Qual Life Res 1995;4:187‑206.
21. Simone IL, CeccarelliA, Tortorella C, BellacosaA, Pellegrini F, 
Plasmati I, et al. Influence of interferon beta treatment on 
quality of life in multiple sclerosis patients. Health Qual Life 
Outcomes 2006;4:96.
22. Pfaffenberger N, Pfeiffer KP, Deibl M, Höfer S, Günther V, 
Ulmer H. Association of factors influencing health‑related 
quality of life in MS. Acta Neurol Scand 2006;114:102‑8.
23. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, 
Stadnyk KJ. A comparison of health utility measures for 
the evaluation of multiple sclerosis treatments. J Neurol 
Neurosurg Psychiatry 2005;76:58‑63